JP2024519585A5 - - Google Patents

Info

Publication number
JP2024519585A5
JP2024519585A5 JP2023570050A JP2023570050A JP2024519585A5 JP 2024519585 A5 JP2024519585 A5 JP 2024519585A5 JP 2023570050 A JP2023570050 A JP 2023570050A JP 2023570050 A JP2023570050 A JP 2023570050A JP 2024519585 A5 JP2024519585 A5 JP 2024519585A5
Authority
JP
Japan
Prior art keywords
antibody
cancer
adc
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023570050A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024519585A (ja
JP7905974B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/092473 external-priority patent/WO2022237874A1/en
Publication of JP2024519585A publication Critical patent/JP2024519585A/ja
Publication of JP2024519585A5 publication Critical patent/JP2024519585A5/ja
Application granted granted Critical
Publication of JP7905974B2 publication Critical patent/JP7905974B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023570050A 2021-05-13 2022-05-12 抗p-カドヘリン抗体を含む抗体コンジュゲートおよびその使用 Active JP7905974B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/093652 2021-05-13
CN2021093652 2021-05-13
PCT/CN2022/092473 WO2022237874A1 (en) 2021-05-13 2022-05-12 Antibody conjugate comprising anti-p-cadherin antibody and uses thereof

Publications (3)

Publication Number Publication Date
JP2024519585A JP2024519585A (ja) 2024-05-17
JP2024519585A5 true JP2024519585A5 (cg-RX-API-DMAC7.html) 2025-03-12
JP7905974B2 JP7905974B2 (ja) 2026-08-17

Family

ID=

Similar Documents

Publication Publication Date Title
RU2008141171A (ru) Анти-тат226 антитела и иммуноконъюгаты
RU2483080C2 (ru) Антитела и иммуноконъюгаты и их применение
US9951133B2 (en) Anti-CD33 antibodies and immunoconjugates
AU2012235817B2 (en) Antibody-drug conjugates
JP2012522513A5 (cg-RX-API-DMAC7.html)
CA3176248A1 (en) Charge variant linkers
JP2014139173A5 (cg-RX-API-DMAC7.html)
JP2013056896A5 (cg-RX-API-DMAC7.html)
JP2012522512A5 (cg-RX-API-DMAC7.html)
FI3930847T3 (fi) Korkea-affiinisia anti-MERTK-vasta-aineita ja niiden käyttöjä
JP2023500875A5 (cg-RX-API-DMAC7.html)
JP2020526584A5 (cg-RX-API-DMAC7.html)
KR20150006000A (ko) 항-pmel17 항체 및 면역접합체
JP2018520092A5 (cg-RX-API-DMAC7.html)
CN111110862A (zh) 抗cldn18.2抗体的药物偶联体及其制备方法和用途
HRP20171789T1 (hr) Konjugati humanog protutijela s lijekom protiv tkivnog faktora
JP2014520088A5 (cg-RX-API-DMAC7.html)
RU2009136946A (ru) Композиции и способы диагностики и лечения опухоли
JP2018520991A5 (cg-RX-API-DMAC7.html)
JP2016063817A5 (cg-RX-API-DMAC7.html)
JP2018516539A (ja) 抗c−Met抗体および抗c−Met抗体−細胞毒性薬物複合体ならびにそれらの医薬用途
HRP20220172T1 (hr) Protutijela protiv cd71 koja se mogu aktivirati, te postupci njihove uporabe
JP2018509146A (ja) Flt3タンパク質に結合する抗体薬物複合体(adc)
RU2020124944A (ru) Антитела против egfr и конъюгаты антитело-лекарственное средство
RU2011144119A (ru) АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ